全文获取类型
收费全文 | 14144篇 |
免费 | 854篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 93篇 |
儿科学 | 328篇 |
妇产科学 | 136篇 |
基础医学 | 1770篇 |
口腔科学 | 268篇 |
临床医学 | 968篇 |
内科学 | 3399篇 |
皮肤病学 | 343篇 |
神经病学 | 1075篇 |
特种医学 | 564篇 |
外科学 | 2674篇 |
综合类 | 68篇 |
预防医学 | 420篇 |
眼科学 | 241篇 |
药学 | 1259篇 |
中国医学 | 19篇 |
肿瘤学 | 1435篇 |
出版年
2023年 | 207篇 |
2022年 | 361篇 |
2021年 | 630篇 |
2020年 | 292篇 |
2019年 | 387篇 |
2018年 | 437篇 |
2017年 | 326篇 |
2016年 | 356篇 |
2015年 | 366篇 |
2014年 | 442篇 |
2013年 | 537篇 |
2012年 | 816篇 |
2011年 | 861篇 |
2010年 | 491篇 |
2009年 | 374篇 |
2008年 | 676篇 |
2007年 | 619篇 |
2006年 | 602篇 |
2005年 | 620篇 |
2004年 | 558篇 |
2003年 | 497篇 |
2002年 | 507篇 |
2001年 | 352篇 |
2000年 | 380篇 |
1999年 | 332篇 |
1998年 | 138篇 |
1997年 | 115篇 |
1996年 | 102篇 |
1995年 | 95篇 |
1994年 | 83篇 |
1993年 | 67篇 |
1992年 | 264篇 |
1991年 | 206篇 |
1990年 | 240篇 |
1989年 | 191篇 |
1988年 | 177篇 |
1987年 | 188篇 |
1986年 | 149篇 |
1985年 | 168篇 |
1984年 | 95篇 |
1983年 | 71篇 |
1982年 | 49篇 |
1979年 | 87篇 |
1978年 | 50篇 |
1977年 | 46篇 |
1974年 | 44篇 |
1973年 | 34篇 |
1972年 | 40篇 |
1970年 | 33篇 |
1969年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
151.
Wada Takehiko Ishimoto Takuji Nakaya Izaya Kawaguchi Takehiko Sofue Tadashi Shimizu Sayaka Kurita Noriaki Sasaki Sho Nishiwaki Hiroki Koizumi Masahiro Saito Shoji Nishibori Nobuhiro Oe Yuji Yoshida Mai Miyaoka Yoshitaka Akiyama Shin’ichi Itano Yuya Okazaki Masaki Ozeki Takaya Ichikawa Daisuke Oguchi Hideyo Kohsaka Satoshi Kosaka Shiho Kataoka Yuki Shima Hideaki Shirai Sayuri Sugiyama Kazuhiro Suzuki Tomo Son Daisuke Tanaka Tomomi Nango Eishu Niihata Kakuya Nishijima Yoko Nozu Kandai Hasegawa Midori Miyata Rei Yazawa Masahiko Yamamoto Yoshihiro Yamamoto Ryohei Shibagaki Yugo Furuichi Kengo Okada Hirokazu Narita Ichiei 《Clinical and experimental nephrology》2021,25(12):1277-1285
Clinical and Experimental Nephrology - 相似文献
152.
Kosuke Ebina Hideki Tsuboi Yoshio Nagayama Masafumi Kashii Shoichi Kaneshiro Akira Miyama Hiroyuki Nakaya Yasuo Kunugiza Makoto Hirao Gensuke Okamura Yuki Etani Kenji Takami Atsushi Goshima Taihei Miura Ken Nakata Seiji Okada 《Joint, bone, spine : revue du rhumatisme》2021,88(5):105219
ObjectivesTo investigate the effects of prior treatment and determine the predictors of a 12-month treatment response of romosozumab (ROMO) in 148 patients with postmenopausal osteoporosis.MethodsIn this prospective, observational, and multicenter study, treatment naïve patients (Naïve; n = 50) or patients previously treated with bisphosphonates (BP; n = 37) or denosumab (DMAb; n = 45) or teriparatide (TPTD; n = 16) (mean age, 75.0 years; T-scores of the lumbar spine [LS] ?3.2 and total hip [TH] ?2.6) were switched to ROMO due to insufficient effects of prior treatment. Bone mineral density (BMD) and serum bone turnover markers were evaluated for 12 months.ResultsAt 12 months, changes in LS BMD were Naïve (18.2%), BP (10.2%), DMAb (6.4%), and TPTD (11.2%) (P < 0.001 between groups) and changes in TH BMD were Naïve (5.6%), BP (3.3%), DMAb (0.6%), and TPTD (4.4%) (P < 0.01 between groups), respectively. In all groups, the LS BMD significantly increased from baseline at 6 and 12 months, although only the DMAb group failed to obtain a significant increase in TH BMD during 12-month treatment. Mean values of N-terminal type I procollagen propeptide (PINP; μg/L) from baseline → 1 month → 12 months were Naïve (67.9 → 134.1 → 51.0), BP (32. 2 → 81.7 → 40.9), DMAb (30.4 → 56.2 → 75.3), and TPTD (97.4 → 105.1 → 37.1), and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b; mU/dL) were Naïve (500.4 → 283.8 → 267.1), BP (273.4 → 203.1 → 242.0), DMAb (220.3 → 246.1 → 304.8), and TPTD (446.6 → 305.1 → 235.7), respectively. Multiple regression analysis revealed that the significant predictors of BMD change at 12 months were difference of prior treatment (r = ?2.8, P < 0.001) and value of PINP at 1 month (r = 0.04, P < 0.01) for LS, and difference of prior treatment (r = ?1.3, P < 0.05) and percentage change of TRACP-5b at 1 month (r = ?0.06, P < 0.05) for TH.ConclusionsThe early effects of ROMO on LS and TH BMD increase at 12 months were significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. 相似文献
153.
Go Anan Hiromichi Iwamura Jotaro Mikami Yuki Kohada Jun Ito Yasuhiro Kaiho Makoto Sato 《Translational andrology and urology》2021,10(2):775
BackgroundHolmium laser enucleation of the prostate (HoLEP) has been a widely utilized minimally invasive surgical procedure for benign prostate hyperplasia. The current study aimed to compare surgical outcomes and King’s Health Questionnaire (KHQ) assessment scores following HoLEP between younger men and those aged ≥75 years.MethodsThis prospective single-center study compared perioperative complications, postoperative urinary conditions, and KHQ scores (nine categories) between men aged ≥75 years (group A) and men aged <75 years (group B) before and 1, 3, and 6 months after surgery.ResultsA total of 100 patients were included for analysis (group A, n=38 and group B, n=62). No differences in patient backgrounds, perioperative complications, such as perioperative decrease in hemoglobin, postoperative fever, postoperative indwelling catheterization duration, or postoperative hospitalization duration, and KHQ were observed between both groups. Both groups showed significantly better International Prostate Symptom Scores, quality of life, maximum urinary flow rate, and postvoid residual volume 1, 3, and 6 months after HoLEP compared to their respective preoperative levels (P<0.01). Regarding KHQ categories, both groups showed significantly better general health perceptions, impact on life, emotions, and sleep/energy 1 month after HoLEP; role limitations, physical limitations, and social limitations 3 months after HoLEP; and personal relationships and incontinence severity measures 6 months after HoLEP compared to their respective preoperative levels (P<0.05).ConclusionsHoLEP could be safe and effective even for men aged ≥75 years, comparing complications, urinary condition, and KHQ scores. 相似文献
154.
Masayuki Tomioka Tohru Yoneyama Yuki Tobisawa Kota Kawase Chie Nakai Manabu Takai Daiki Kato Koji Iinuma Keita Nakane Kosuke Mizutani Yasuhiro Hashimoto Takuya Koie 《Translational andrology and urology》2021,10(3):1192
BackgroundAlthough the patients with muscle-invasive bladder cancer (MIBC) generally have poor prognosis, the utility of these biomarkers for the prediction of oncological outcomes in MIBC has not been completely explored. Ghrelin regulates processes associated with cancer, including cell proliferation, apoptosis, cell migration, cell invasion, and angiogenesis. Thus, we aimed to evaluate the impact of serum ghrelin levels on survival in MIBC.MethodsIn this study, we reviewed the clinical and pathological records of 56 patients who were diagnosed with MIBC between November 2015 and November 2019 at Gifu and Hirosaki University Hospitals. We focused on 27 patients who had received chemotherapy and collected blood samples before and after chemotherapy. Blood samples were collected before chemotherapy and after completing two cycles of chemotherapy. Serum acyl (AG) and desacyl ghrelin (DG) were measured using AG and DG enzyme-linked immunosorbent assay kits (SCETI, Tokyo, Japan), respectively.ResultsThe 3-year overall and progression-free survival (PFS) rates were 82.9% and 68.3%, respectively. According to the AG level after chemotherapy, the 3-year PFS rates were 77.5% and 53.0% in patients with AG levels ≥1.34 and <1.34 pg/mL, respectively (P=0.038). With regard to DG levels after chemotherapy, the 3-year PFS rates were 90.9% and 43.3% in patients with DG levels <92.3 and ≥92.3 pg/mL, respectively (P=0.039). On multivariate analysis, serum AG levels were significantly associated with PFS.ConclusionsThis study suggested the usefulness of the ghrelin as a prognostic predictor of PFS in patients with MIBC. 相似文献
155.
156.
Yuki Tajika Tohru Murakami Mahito Sato Fumitaka Kubota Hiroshi Yorifuji 《Developmental dynamics》2008,237(7):1886-1892
Vesicle-associated membrane protein 2 (VAMP2) is a member of the SNARE family of proteins that regulate the intracellular vesicle fusion process. This study investigated the developmental expression of VAMP2 in the rat embryo. In the trunk, VAMP2 was primarily found in the heart on embryonic day (E) 10. On E12.5, VAMP2 expression was found in nerve fibers, somites, and heart. In somites, epithelial cells in the dorsomedial lip, and elongated myoblasts in myotome were positive for VAMP2. On E16.5, VAMP2 was expressed in the heart, nerve fibers, and skeletal muscles. In skeletal muscles, multinuclear myotubes were positive for VAMP2. In the head, where muscles are derived both from somitic and non-somitic origin, VAMP2 was found in myotubes of the extrinsic ocular muscles and masseter muscle on E16.5. These findings suggest the involvement of VAMP2 in the development of skeletal muscles of somitic and non-somitic origins. 相似文献
157.
S Minoshima T Shiina I Yamagami Y Kitakata K Isobe K Uno Y Anzai J Okada Y Uchida J Itami 《Kaku igaku. The Japanese journal of nuclear medicine》1990,27(7):749-756
SPECT with N-isopropyl-p-[I-123]iodoamphetamine were performed in a 81-year-old man with cerebral infarction. In the subacute phase, the radioactivity was increased in the infarct area where fogging effect and remarkable contrast enhancement was demonstrated in X-ray CT. The contralateral cerebellar hemisphere showed reduced activity due to crossed cerebellar diaschisis (CCD). In the chronic phase, the decrement of the activity in the infarct was observed. Increased activity in the subacute phase was thought to reflect the hyperemia in the infarct, while CCD suggested the decreased metabolic activity in the lesion. The coexistence of the hyperemia and the CCD indicates flow and metabolic uncoupling, which means "luxury perfusion". This case was also thought to demonstrate atypical findings of CCD in SPECT imaging. 相似文献
158.
Yokoyama I Uchida K Tominaga Y Asano H Orihara A Takagi H 《Clinical transplantation》1993,7(3):258-262
One-hundred-and-twenty patients underwent first cadaveric kidney transplantation from the non-heart beating donors. All of the organs were procured with the use of double balloon catheter for in situ cooling. The mean warm ischemic time and cold ischemic time were 10.7 +/- 17.0 minutes and 18.9 +/- 11.4 hours, respectively. One- and 5-year graft survival rates were 85.0 and 72.7%, respectively. Among 120 recipients, 30 (25%) grafts functioned immediately (immediate function), 82 (68.3%) grafts functioned after varying length of oliguric periods (delayed function) and 8 (6.7%) grafts never functioned (non-function). The mean age of the donors in the group of immediate function (31.5 +/- 16.1 yr) was significantly lower than those of other two groups. The mean warm ischemic time in the group of immediate function (6.0 +/- 11.2 min) was significantly shorter than that of delayed function. However, there was no significant difference in donor hypotensive episode, types of preservation fluid and cold ischemic time between the groups. The conclusion is that the ultimate result of cadaveric kidney transplant from the non-heart beating donors with the use of double lumen catheter is acceptable despite a relatively high incidence of delayed graft function. 相似文献
159.
Tomomi Nakagawa Kazuyoshi Shigehara Yuki Kato Shohei Kawaguchi Hiroki Nakata Taito Nakano Kouji Izumi Yoshifumi Kadono Atsushi Mizokami 《Journal of medical virology》2023,95(1):e28110
Although urine and bladder washing samples are commonly used for the cytological evaluation of the bladder mucosa, it has been unknown whether these samples are likely suitable to investigate human papillomavirus (HPV) prevalence in the urinary bladder. The present study aimed to elucidate the appropriateness of spontaneously voided urine or bladder washing in screening HPV infection in the urinary bladder. Urine and bladder washing samples were obtained from 201 patients who underwent transurethral bladder tumor resection. After extracting DNA from both samples, HPV-DNA was examined using a nested polymerase chain reaction with GP5+/6+ and MY09/11 primers. HPV genotyping was performed in the HPV-positive samples. In situ hybridization (ISH) was performed to observe the HPV-DNA localization in urothelial cells among cytological samples and paraffin-embedded tumor tissues in HPV-positive washing samples. HPV prevalence in urine and washing samples were 9.5% and 7.0%, respectively. High-risk HPV prevalence in urine and washing samples was 7.5% and 4.0%, respectively. The most common HPV type was HPV 16, followed by HPV 52 and HPV 18 in both samples. HPV type distribution in both samples was not in agreement (κ = −0.431). The ISH analysis revealed that HPV-DNA signal was observed in urothelial cells of five (55.7%) of nine detectable HPV-positive cytological samples. Six (66.7%) of nine HPV-positive cases had HPV-DNA signals in tumor tissue. The use of washing samples was likely applicable for investigating HPV prevalence in the urinary bladder. HPV-DNA detected in washing samples might be frequently derived from the urinary bladder. 相似文献
160.
Shun Kaneko Masayuki Kurosaki Toshie Mashiba Hiroyuki Marusawa Masahiko Kondo Yuji Kojima Yasushi Uchida Hideki Fujii Takehiro Akahane Hitoshi Yagisawa Atsunori Kusakabe Haruhiko Kobashi Takehiko Abe Hideo Yoshida Chikara Ogawa Koichiro Furuta Nobuharu Tamaki Keiji Tsuji Tomomichi Matsushita Namiki Izumi the Japanese Red Cross Liver Study Group 《Journal of medical virology》2023,95(1):e28210
Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to identify the risk factors for HCC development in naïve CHB patients treated with current NA. Patients receiving NA (n = 905) were recruited retrospectively from the 17 hospitals of the Japanese Red Cross Liver Study Group. All treatment-naïve patients had been receiving current NA continuously for more than 1 year until the end of the follow-up. We analyzed the accuracy of predictive risk score using the area under receiver operating characteristic curve. The albumin–bilirubin (ALBI) score was significantly improved by NA therapy (−0.171 ± 0.396; p < 0.001 at Week 48). A total of 72 (8.0%) patients developed HCC over a median follow-up of 6.2 (1.03–15.7) years. An independent predictive factor of HCC development was older age, cirrhosis, lower platelet counts at baseline and ALBI score, and alpha-fetoprotein (AFP) at 1 year after NA therapy according to multivariate analysis. The accuracy was assessed using the PAGE-B, mPAGE-B, aMAP, APA-B, and REAL-B scores that included these factors. Discrimination was generally acceptable for these models. aMAP and REAL-B demonstrated high discrimination with 0.866/0.862 and 0.833/0.859 for 3- and 5-year prediction from the status of 1 year after NA therapy, respectively. Baseline age and platelet count, as well as ALBI and AFP one year after NA, were useful for stratifying carcinogenesis risk. The aMAP and REAL-B scores were validated with high accuracy in Japanese CHB patients. 相似文献